News Headlines Article

Afrezza patients worry they’ll lose access to their insulin
Los Angeles Times

As Valencia drugmaker MannKind scrambles to replace the strategic partner it was relying on to market and distribute its Afrezza inhalable insulin treatment, diabetics who have come to rely on the drug are wondering whether they’ll be able to continue using it — despite assurances that it will remain available.

On Twitter, on online diabetes discussion boards and even in a YouTube video parody, Afrezza users also took shots at Sanofi, the French pharmaceutical giant that earlier this week pulled out of the marketing agreement.